CN114174272A - 吡嗪-2(1h)-酮类化合物的制备方法 - Google Patents

吡嗪-2(1h)-酮类化合物的制备方法 Download PDF

Info

Publication number
CN114174272A
CN114174272A CN202080054656.5A CN202080054656A CN114174272A CN 114174272 A CN114174272 A CN 114174272A CN 202080054656 A CN202080054656 A CN 202080054656A CN 114174272 A CN114174272 A CN 114174272A
Authority
CN
China
Prior art keywords
compound
temperature
hours
palladium
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080054656.5A
Other languages
English (en)
Other versions
CN114174272B (zh
Inventor
黄进明
于娟
林锦霞
杨丽美
曾金香
付志飞
罗妙荣
张杨
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Original Assignee
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhangzhou Pientzehuang Pharmaceutical Co Ltd filed Critical Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Publication of CN114174272A publication Critical patent/CN114174272A/zh
Application granted granted Critical
Publication of CN114174272B publication Critical patent/CN114174272B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0255—Phosphorus containing compounds
    • B01J31/0267—Phosphines or phosphonium compounds, i.e. phosphorus bonded to at least one carbon atom, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, the other atoms bonded to phosphorus being either carbon or hydrogen
    • B01J31/0268—Phosphonium compounds, i.e. phosphine with an additional hydrogen or carbon atom bonded to phosphorous so as to result in a formal positive charge on phosphorous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Abstract

提供式(I)化合物及其中间体的制备方法。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202080054656.5A 2019-08-08 2020-08-04 吡嗪-2(1h)-酮类化合物的制备方法 Active CN114174272B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910731662 2019-08-08
CN2019107316629 2019-08-08
CN201911059973 2019-11-01
CN2019110599731 2019-11-01
PCT/CN2020/106895 WO2021023193A1 (zh) 2019-08-08 2020-08-04 吡嗪-2(1h)-酮类化合物的制备方法

Publications (2)

Publication Number Publication Date
CN114174272A true CN114174272A (zh) 2022-03-11
CN114174272B CN114174272B (zh) 2023-05-12

Family

ID=74503862

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080054656.5A Active CN114174272B (zh) 2019-08-08 2020-08-04 吡嗪-2(1h)-酮类化合物的制备方法

Country Status (5)

Country Link
US (1) US11535609B2 (zh)
EP (1) EP4011868A4 (zh)
JP (1) JP7121218B1 (zh)
CN (1) CN114174272B (zh)
WO (1) WO2021023193A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7198387B2 (ja) * 2019-08-08 2022-12-28 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 ピラジン－２（１ｈ）－オン系化合物のｃ結晶形とｅ結晶形及びその製造方法
WO2021023192A1 (zh) * 2019-08-08 2021-02-11 漳州片仔癀药业股份有限公司 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
US11597722B2 (en) * 2019-08-08 2023-03-07 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal form D of pyrazine-2(1H)-ketone compound and preparation method therefor

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058076A1 (en) * 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CN104507943A (zh) * 2012-06-13 2015-04-08 因塞特公司 作为fgfr抑制剂的取代的三环化合物
CN104540809A (zh) * 2012-07-11 2015-04-22 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
CN105658642A (zh) * 2013-10-25 2016-06-08 蓝图药品公司 纤维母细胞生长因子受体抑制剂
CN106459034A (zh) * 2014-02-07 2017-02-22 普林斯匹亚生物制药公司 作为成纤维细胞生长因子受体抑制剂的喹诺酮衍生物
WO2017070708A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CN107438607A (zh) * 2015-02-20 2017-12-05 因赛特公司 作为fgfr抑制剂的双环杂环
WO2018160076A1 (en) * 2017-03-03 2018-09-07 Auckland Uniservices Limited Fgfr kinase inhibitors and pharmaceutical uses
WO2018190349A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
WO2018190326A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286248B2 (en) 2018-02-08 2022-03-29 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058076A1 (en) * 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CN104507943A (zh) * 2012-06-13 2015-04-08 因塞特公司 作为fgfr抑制剂的取代的三环化合物
CN104540809A (zh) * 2012-07-11 2015-04-22 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
CN105658642A (zh) * 2013-10-25 2016-06-08 蓝图药品公司 纤维母细胞生长因子受体抑制剂
CN106459034A (zh) * 2014-02-07 2017-02-22 普林斯匹亚生物制药公司 作为成纤维细胞生长因子受体抑制剂的喹诺酮衍生物
CN107438607A (zh) * 2015-02-20 2017-12-05 因赛特公司 作为fgfr抑制剂的双环杂环
WO2017070708A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2018160076A1 (en) * 2017-03-03 2018-09-07 Auckland Uniservices Limited Fgfr kinase inhibitors and pharmaceutical uses
WO2018190349A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
WO2018190326A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物

Also Published As

Publication number Publication date
EP4011868A1 (en) 2022-06-15
CN114174272B (zh) 2023-05-12
JP2022538931A (ja) 2022-09-06
WO2021023193A1 (zh) 2021-02-11
JP7121218B1 (ja) 2022-08-17
EP4011868A4 (en) 2022-11-09
US11535609B2 (en) 2022-12-27
US20220380350A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CN114174272A (zh) 吡嗪-2(1h)-酮类化合物的制备方法
CN114174271A (zh) 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法
CN105601635B (zh) 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法
JP2003532635A (ja) キナーゼ阻害薬
WO2021004326A1 (zh) 高通量的化合物库构建和筛选方法以及反应装置
CN114174270A (zh) 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
CN114269723A (zh) 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
CN109232363B (zh) 一种3-硒氰基吲哚化合物的合成方法
CN109694335B (zh) 双取代对硝基苯乙腈衍生物的无溶剂制备方法
CN108264502B (zh) 喹啉咔唑类荧光染料及其制法和应用
EP3896063A1 (en) Salt of syk inhibitor and crystalline form thereof
CN115141177B (zh) 喹喔啉类化合物马来酸盐的新晶型及其制备方法
JPWO2017061288A1 (ja) チロシンホスファターゼ及びチロシンキナーゼ活性の測定方法
KR20240004588A (ko) 피롤로피리미딘류 화합물의 결정형 및 이의 제조 방법
CN113024553A (zh) 三唑并四氢-β-咔啉衍生物及其制备方法和应用
JPH08100129A (ja) メロシアニン系標識色素、その前駆体化合物及びメロシアニン系標識色素の合成方法、並びにメロシアニン標識タンパク質

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant